Bristol Myers Squibb to invest MXN 1 billion in Mexico for healthcare manufacturing and clinical research

Bristol Myers Squibb announced an investment of nearly MXN 1 billion in Mexico over the next four years, with the objective of strengthening clinical research, expanding capabilities related to the local manufacturing of innovative therapies and generating new jobs in the country.

The company reported that the project is part of its strategy to reinforce Mexico’s health sovereignty and expand access to specialized treatments within the healthcare sector.

“This project is focused on strengthening Mexico’s health sovereignty through the expansion of and investment in clinical research, as well as the implementation of local manufacturing processes for innovative therapies.”

Bristol Myers Squibb investment drives healthcare manufacturing in Mexico

The global biopharmaceutical company has more than 150 years of history and, in 2026, celebrates 80 years of operations in Mexico. The company participates in therapeutic areas such as oncology, hematology, immunology, cardiovascular diseases and neuroscience.

Oswaldo Bernal highlighted that Bristol Myers Squibb has been a pioneer in immunotherapy, a treatment that represented a turning point in the care of different types of cancer.

“We are pioneers in immunotherapy, a therapy that marked a turning point in the treatment of different types of cancer.”

Clinical research and scientific talent strengthen the pharmaceutical sector

The executive indicated that the investment will be aligned with the objectives of the so-called Plan Mexico and will contribute to the development of local capabilities for research and production in the healthcare sector.

He also noted that the country’s infrastructure and availability of specialized scientific talent position Mexico as a strategic point for clinical research and development activities.

“Mexico’s infrastructure and its exceptional scientific talent make it a strategic point for clinical research and development.”

Bernal also recognized the progress made in public policies related to health and access to innovative therapies, as well as the collaboration between authorities and companies in the sector to expand the availability of treatments for patients in Mexico.